… all patients according to different lines of gefitinib or erlotinib. The disparities of choices on
gefitinib or erlotinib (more male, non-adenocarcinoma and smokers using erlotinib) were still …

… of disease after discontinuation of erlotinib or gefitinib in patients who had initially … patients
with acquired resistance to erlotinib or gefitinib, continued treatment with erlotinib or gefitinib …

… on PFS or OS in patients treated with EGFR-TKIs. Erlotinib, gefitinib, and afatinib showed …
significantly longer in patients with the exon 19 deletion compared to patients with the exon …

… trial, patients treated with either gefitinib or erlotinib were pooled for purposes of this analysis.
PFS6 and response rate were determined based on the proportion of patients known to …

… patients with EGFR-wt only, as gefitinib and erlotinib are well known to induce a marked
response and long PFS in patients … of the two agents directly in patients with EGFR-wt NSCLC. …

… NCT01024413) comparing erlotinib with gefitinib for patients with exon 21 mutations. The …
patients with advanced NSCLC were allowed to be recruited into this phase III trial. All patients …

… Some of these patients received EGFR TKIs gefitinib or erlotinib pre and/or postoperatively
… trial of perioperative gefitinib. The surgical database prospectively captures patient sex, age, …

… This is the first phase II trial for evaluating the efficacy and safety of pemetrexed in combination
with gefitinib or erlotinib after the relapse to gefitinib or erlotinib treatments in patients with …

… In this study, patients with advanced NSCLC were randomized to erlotinib or placebo in …
4.7 months for erlotinib and placebo, respectively (HR: 0.70; p < .001). Indications for erlotinib in …

… clear whether gefitinib or erlotinib has different activities in advanced NSCLC patients with
… We review the published clinical trials that used gefitinib or erlotinib in NSCLC and compare …